rs122460159
Variant summary
Our verdict is Pathogenic. Variant got 14 ACMG points: 14P and 0B. PM1PP3_StrongPP5_Very_Strong
The NM_001323289.2(CDKL5):c.119C>T(p.Ala40Val) variant causes a missense change involving the alteration of a non-conserved nucleotide. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Pathogenic (★★★). Synonymous variant affecting the same amino acid position (i.e. A40A) has been classified as Likely benign.
Frequency
Genomes: not found (cov: 21)
Exomes 𝑓: 0.0 ( 0 hom. 0 hem. )
Failed GnomAD Quality Control
Consequence
CDKL5
NM_001323289.2 missense
NM_001323289.2 missense
Scores
9
5
2
Clinical Significance
Conservation
PhyloP100: 3.38
Genes affected
CDKL5 (HGNC:11411): (cyclin dependent kinase like 5) This gene is a member of Ser/Thr protein kinase family and encodes a phosphorylated protein with protein kinase activity. Mutations in this gene have been associated with X-linked infantile spasm syndrome (ISSX), also known as X-linked West syndrome, and Rett syndrome (RTT). Alternate transcriptional splice variants have been characterized. [provided by RefSeq, Jul 2008]
Genome browser will be placed here
ACMG classification
Classification made for transcript
Verdict is Pathogenic. Variant got 14 ACMG points.
PM1
?
In a hotspot region, there are 5 aminoacids with missense pathogenic changes in the window of +-8 aminoacids around while only 0 benign, 2 uncertain in NM_001323289.2
PP3
?
MetaRNN computational evidence supports a deleterious effect, 0.985
PP5
?
Variant X-18564496-C-T is Pathogenic according to our data. Variant chrX-18564496-C-T is described in ClinVar as [Pathogenic]. Clinvar id is 11502.Status of the report is reviewed_by_expert_panel, 3 stars. Variant chrX-18564496-C-T is described in Lovd as [Pathogenic]. Variant chrX-18564496-C-T is described in Lovd as [Likely_pathogenic].
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | UniProt |
---|---|---|---|---|---|---|---|
CDKL5 | NM_001323289.2 | c.119C>T | p.Ala40Val | missense_variant | 4/18 | ENST00000623535.2 | |
CDKL5 | NM_001037343.2 | c.119C>T | p.Ala40Val | missense_variant | 5/22 | ||
CDKL5 | NM_003159.3 | c.119C>T | p.Ala40Val | missense_variant | 4/21 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|
CDKL5 | ENST00000623535.2 | c.119C>T | p.Ala40Val | missense_variant | 4/18 | 1 | NM_001323289.2 | P1 |
Frequencies
GnomAD3 genomes ? Cov.: 21
GnomAD3 genomes
?
Cov.:
21
GnomAD4 exome Data not reliable, filtered out with message: AC0 AF: 0.00 AC: 0AN: 1007577Hom.: 0 Cov.: 19 AF XY: 0.00 AC XY: 0AN XY: 293709
GnomAD4 exome
Data not reliable, filtered out with message: AC0
AF:
AC:
0
AN:
1007577
Hom.:
Cov.:
19
AF XY:
AC XY:
0
AN XY:
293709
Gnomad4 AFR exome
AF:
Gnomad4 AMR exome
AF:
Gnomad4 ASJ exome
AF:
Gnomad4 EAS exome
AF:
Gnomad4 SAS exome
AF:
Gnomad4 FIN exome
AF:
Gnomad4 NFE exome
AF:
Gnomad4 OTH exome
AF:
GnomAD4 genome ? Cov.: 21
GnomAD4 genome
?
Cov.:
21
ClinVar
Significance: Pathogenic
Submissions summary: Pathogenic:7
Revision: reviewed by expert panel
LINK: link
Submissions by phenotype
Developmental and epileptic encephalopathy, 2 Pathogenic:3
Pathogenic, no assertion criteria provided | literature only | OMIM | Oct 01, 2009 | - - |
Pathogenic, no assertion criteria provided | curation | RettBASE | Mar 13, 2014 | In vitro study shows mislocalisation of CDKL5 in the cytoplasm - |
Pathogenic, criteria provided, single submitter | clinical testing | Génétique des Maladies du Développement, Hospices Civils de Lyon | Jun 29, 2017 | - - |
CDKL5 disorder Pathogenic:1
Pathogenic, reviewed by expert panel | curation | ClinGen Rett and Angelman-like Disorders Variant Curation Expert Panel | Mar 30, 2021 | The p.Ala40Val variant in CDKL5 has been reported in at least 4 unconfirmed de novo occurrences in patients with CDKL5 disorder (PMID 27779742, 17993579, 22678952, 19793311) (PM6_VS). It is also reported in the mosaic state in a male patient with CDKL5 disorder (PMID 25819767) and therefore confirmed to be de novo (PS2). The p.Ala40Val variant has been observed in at least 10 other individuals with CDKL5 disorder (27779742, 25819767, 17993579, 22678952, 19793311, 21309761, 19780792) (PS4). The variant is absent in gnomAD (PM2_supporting). The variant is located in a well-characterized (ATP binding region: aa 19-43) functional domain of CDKL5 (PMID: 28544139, 17993579, 23064044, 29264392) (PM1). Computational prediction analysis tools suggests a deleterious impact; however, this information does not predict clinical significance on its own (PP3). In summary, the p.Ala40Val in CDKL5 is classified as Pathogenic based on the ACMG/AMP criteria (PM6_very strong, PS2, PS4_strong, PM1, PM2_supporting, PP3). - |
not provided Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | GeneDx | Jan 17, 2022 | Published functional studies demonstrate that A40V results in the mislocalization of the CDKL5 protein (Rosas-Vargas et al., 2008); Not observed in large population cohorts (gnomAD); In silico analysis, which includes protein predictors and evolutionary conservation, supports a deleterious effect; This variant is associated with the following publications: (PMID: 25819767, 17993579, 27848944, 27779742, 19793311, 19780792, 22678952, 22779007, 33047306, 31302675, 30898514) - |
Atypical Rett syndrome Pathogenic:1
Pathogenic, no assertion criteria provided | curation | RettBASE | Mar 13, 2014 | In vitro study shows mislocalisation of CDKL5 in the cytoplasm - |
Developmental and epileptic encephalopathy, 2;CN128785:Angelman syndrome-like Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Invitae | Aug 05, 2023 | For these reasons, this variant has been classified as Pathogenic. This variant disrupts the p.Ala40 amino acid residue in CDKL5. Other variant(s) that disrupt this residue have been determined to be pathogenic (PMID: 27848944). This suggests that this residue is clinically significant, and that variants that disrupt this residue are likely to be disease-causing. Experimental studies have shown that this missense change affects CDKL5 function (PMID: 17993579, 19793311). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is expected to disrupt CDKL5 protein function. ClinVar contains an entry for this variant (Variation ID: 11502). This missense change has been observed in individuals with CDKL5-related disorders (PMID: 17993579, 19780792, 22678952, 25819767). This variant is not present in population databases (gnomAD no frequency). This sequence change replaces alanine, which is neutral and non-polar, with valine, which is neutral and non-polar, at codon 40 of the CDKL5 protein (p.Ala40Val). - |
Computational scores
Source:
Name
Calibrated prediction
Score
Prediction
AlphaMissense
Pathogenic
BayesDel_addAF
Pathogenic
D
BayesDel_noAF
Pathogenic
Cadd
Pathogenic
Dann
Uncertain
DEOGEN2
Benign
T;T;.;T;.;.;.;.
FATHMM_MKL
Uncertain
D
M_CAP
Pathogenic
D
MetaRNN
Pathogenic
D;D;D;D;D;D;D;D
MetaSVM
Uncertain
D
MutationAssessor
Uncertain
M;.;.;M;.;.;.;M
MutationTaster
Benign
A;A
PrimateAI
Pathogenic
D
PROVEAN
Uncertain
D;.;.;D;.;.;.;.
REVEL
Pathogenic
Sift
Pathogenic
D;.;.;D;.;.;.;.
Sift4G
Pathogenic
D;.;.;D;D;D;D;D
Polyphen
D;.;.;D;.;.;.;.
Vest4
MutPred
Loss of ubiquitination at K45 (P = 0.1216);Loss of ubiquitination at K45 (P = 0.1216);Loss of ubiquitination at K45 (P = 0.1216);Loss of ubiquitination at K45 (P = 0.1216);Loss of ubiquitination at K45 (P = 0.1216);Loss of ubiquitination at K45 (P = 0.1216);Loss of ubiquitination at K45 (P = 0.1216);Loss of ubiquitination at K45 (P = 0.1216);
MVP
MPC
2.4
ClinPred
D
GERP RS
RBP_binding_hub_radar
RBP_regulation_power_radar
Varity_R
gMVP
Splicing
Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
Details are displayed if max score is > 0.2
Find out detailed SpliceAI scores and Pangolin per-transcript scores at